Anavex Life Sciences Corp (AVXL)
3.635
-0.16
(-4.34%)
USD |
NASDAQ |
Apr 19, 13:22
Anavex Life Sciences Total Liabilities (Quarterly): 12.50M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 12.50M |
September 30, 2023 | 12.53M |
June 30, 2023 | 11.06M |
March 31, 2023 | 14.02M |
December 31, 2022 | 13.25M |
September 30, 2022 | 10.21M |
June 30, 2022 | 9.484M |
March 31, 2022 | 8.071M |
December 31, 2021 | 10.53M |
September 30, 2021 | 10.80M |
June 30, 2021 | 9.274M |
March 31, 2021 | 7.764M |
December 31, 2020 | 8.034M |
September 30, 2020 | 7.306M |
June 30, 2020 | 6.949M |
March 31, 2020 | 6.229M |
December 31, 2019 | 5.464M |
September 30, 2019 | 5.040M |
June 30, 2019 | 4.337M |
March 31, 2019 | 6.371M |
December 31, 2018 | 4.876M |
September 30, 2018 | 3.885M |
June 30, 2018 | 3.209M |
March 31, 2018 | 3.417M |
December 31, 2017 | 2.798M |
Date | Value |
---|---|
September 30, 2017 | 3.584M |
June 30, 2017 | 1.455M |
March 31, 2017 | 2.120M |
December 31, 2016 | 2.195M |
September 30, 2016 | 3.190M |
June 30, 2016 | 2.173M |
March 31, 2016 | 2.432M |
December 31, 2015 | 2.533M |
September 30, 2015 | 2.661M |
June 30, 2015 | 1.410M |
March 31, 2015 | 1.662M |
December 31, 2014 | 6.577M |
September 30, 2014 | 7.161M |
June 30, 2014 | 1.905M |
March 31, 2014 | 1.884M |
December 31, 2013 | 1.821M |
September 30, 2013 | 2.857M |
June 30, 2013 | 3.557M |
March 31, 2013 | 3.435M |
December 31, 2012 | 3.409M |
September 30, 2012 | 2.888M |
June 30, 2012 | 2.220M |
March 31, 2012 | 3.120M |
December 31, 2011 | 2.566M |
September 30, 2011 | 1.345M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
4.337M
Minimum
Jun 2019
14.02M
Maximum
Mar 2023
9.097M
Average
9.274M
Median
Jun 2021
Total Liabilities (Quarterly) Benchmarks
Ventyx Biosciences Inc | 33.77M |
Vertex Pharmaceuticals Inc | 5.150B |
Sarepta Therapeutics Inc | 2.405B |
Checkpoint Therapeutics Inc | 18.42M |
NovaBay Pharmaceuticals Inc | 5.72M |
Total Liabilities (Quarterly) Related Metrics
Total Assets (Quarterly) | 148.07M |
Shareholders Equity (Quarterly) | 135.58M |